Dosing Regimens Before and During Long-Term Treatment with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A: An Updated Analysis of the ASPIRE Study

被引：0
|
作者：
Nolan, B. [1 ]
Young, G. [2 ]
Mahlangu, J. N. [3 ,4 ]
Liesner, R. [5 ]
Pasi, K. J. [6 ]
Yuan, H. [7 ]
Winding, B. [8 ]
Ramirez-Santiago, A. [7 ]
Dumont, J. [7 ]
Lethagen, S. [8 ,9 ]
Glazebrook, D. V. [7 ]
机构：
[1] Our Ladys Childrens Hosp, Dublin, Ireland
[2] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[3] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
[4] Univ Witwatersrand, Natl Hlth Lab Serv, Johannesburg, South Africa
[5] Great Ormond St Hosp Sick Children, London, England
[6] Barts & London Comprehens Care Ctr, London, England
[7] Biogen, Cambridge, MA USA
[8] Sobi, Stockholm, Sweden
[9] Univ Copenhagen, Copenhagen, Denmark
来源：
HAEMOPHILIA | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P023
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [1] Dosing Regimens Before and During Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFC) in Adults And Adolescents With Severe Haemophilia A: an Updated Analysis Of The Aspire Study
    Pasi, K. J.
    Perry, D.
    Mahlangu, J. N.
    Konkle, B.
    Rangarajan, S.
    Hanabusa, H.
    Pabinger, I.
    Brown, S. A.
    Yuan, H.
    Winding, B.
    Ramirez-Santiago, A.
    Lethagen, S.
    Glazebrook, D. V.
    HAEMOPHILIA, 2017, 23 : 89 - 90
  • [2] Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in children with severe hemophilia A
    Nolan, Beatrice
    Liesner, Raina
    Young, Guy
    Mahlangu, Johnny
    Pasi, K. John
    Lethagen, Stefan
    Cristiano, Lynda M.
    Yuan, Huixing
    Pierce, Glenn F.
    Allen, Geoffrey
    HAEMOPHILIA, 2016, 22 : 48 - 49
  • [3] Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Adults and Adolescents with Severe Haemophilia A: An Updated Interim Analysis of the Aspire Study
    Pasi, K. J.
    Perry, D. J.
    Mahlangu, J.
    Konkle, B. A.
    Rangarajan, S.
    Brown, S. A.
    Hanabusa, H.
    Jackson, S.
    Pabinger, I.
    Cristiano, L. M.
    Lethagen, S.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 64 - 65
  • [4] Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in adults and adolescents with severe hemophilia A
    Konkle, Barbara A.
    Pasi, K. John
    Perry, David J.
    Mahlangu, Johnny
    Rangarajan, Savita
    Hanabusa, Hideji
    Pabinger, Ingrid
    Lethagen, Stefan
    Cristiano, Lynda M.
    Yuan, Huixing
    Pierce, Glenn F.
    Allen, Geoffrey
    HAEMOPHILIA, 2016, 22 : 44 - 44
  • [5] Second Interim Analysis of the Aspire Study Evaluating Long-Term Safety and Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A
    Nolan, B.
    Young, G.
    Mahlangu, J.
    Liesner, R.
    Pasi, K. J.
    Lethagen, S.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 65 - 66
  • [6] Interim Analysis Of The ASPIRE Study Evaluating Long-term Safety And Efficacy Of Recombinant Factor VIII FC (RFVIIIFC) In Children With Severe Haemophilia A
    Nolan, B.
    Young, G.
    Mahlangu, J.
    Liesner, R.
    Pasi, J.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 58 - 59
  • [7] Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study
    Pasi, J.
    Perry, D.
    Mahlangu, J.
    Konkle, B.
    Rangarajan, S.
    Brown, S. A.
    Hanabusa, H.
    Jackson, S.
    Pabinger-Fasching, I.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 52 - 53
  • [8] Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A
    Nolan, B.
    Mahlangu, J.
    Perry, D.
    Young, G.
    Liesner, R.
    Konkle, B.
    Rangarajan, S.
    Brown, S.
    Hanabusa, H.
    Pasi, K. J.
    Pabinger, I.
    Jackson, S.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 (01) : 72 - 80
  • [9] Long-term efficacy and safety of prophylactic treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe haemophilia A: Final longitudinal analysis of A-LONG/kids A-LONG and ASPIRE
    Konkle, B.
    Young, G.
    Liesner, R.
    Mahlangu, J.
    Brown, S. A.
    Nolan, B.
    Tripkovic, N.
    Feng, J.
    Barnowski, C.
    HAEMOPHILIA, 2019, 25 : 55 - 55
  • [10] Perioperative Management Of Subjects With Haemophilia A In The ASPIRE Study With Long-acting Recombinant Factor VIII FC Fusion Protein (rFVIIIFc)
    Mahlangu, J.
    Ragni, M.
    Gupta, N.
    Rangarajan, S.
    Nogami, K.
    Li, X.
    Allen, G.
    Pierce, G. F.
    Robinson, B.
    HAEMOPHILIA, 2015, 21 : 82 - 82
12345